Healios KK ( (JP:4593) ) has issued an announcement.
Healios K.K. announced the expansion of its subsidiary ProcellCure’s role by incorporating a Contract Development and Manufacturing Organization (CDMO) function. This strategic move aims to optimize the manufacturing processes for cellular pharmaceutical products and enhance group-wide manufacturing capacity. This shift follows the cancellation of a planned Phase 3 ARDS clinical trial in Japan and signifies a pivot in ProcellCure’s business focus. The change is not expected to impact Healios’ financial results for the fiscal year ending December 2025.
More about Healios KK
Healios K.K. operates within the biotechnology industry, focusing on developing cell production technologies including induced pluripotent stem cells, universal donor cells, and multipotent adult progenitor cells. The company’s market focus includes regenerative medicine products, particularly the proprietary MultiStem technology for treating conditions like ischemic stroke and acute respiratory distress syndrome (ARDS).
YTD Price Performance: 7.91%
Average Trading Volume: 988,318
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen17.22B
Find detailed analytics on 4593 stock on TipRanks’ Stock Analysis page.